Single-center, open-label, 2-sequence, 3-period crossover drug-drug interaction study. Repeated doses of POL7080 and repeated doses of amikacin will be administered alone or combined. In total, 14 subjects will be enrolled to obtain at least 10 evaluable subjects. The study consists of an eligibility screening period, up to 3 treatments periods and a follow-up visit.

Inclusion Criteria:

• Healthy male and female (of non-childbearing potential) subjects between 18 to 55 years of age (inclusive)
• BMI between 18.0-30.0 kg/m2
• Creatinine clearance estimated by Cockroft Gault formula > 80 mL/min and < 160 ml/min (for males), or < 150ml/min (females)
• Non smokers
• Normal audiogram.

Exclusion Criteria:

• History or suspicion of alcohol and/or drug abuse in the last 5 years
• Within 2 months prior to screening: exposure to aminoglycoside antibiotic, chemotherapy, or current use of loop diuretics
• Regular consumption of large amounts of xanthine
• Any medication that inhibits active tubular secretion within 4 weeks prior to first dosing
• Infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV)
• Any signs of renal impairment
• Clinically significant abnormalities (e.g. cardiovascular, laboratory values)
• Clinically significant abnormal ECG